TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06189963: Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

Sponsor: NKGen Biotech, Inc. · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,253,240

Rescue Site Savings

+$824,500

Unlock Full NCT06189963 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06189963 Rescue Dossier →